The Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened safety warnings for gabapentinoids, benzodiazepines, and z-drugs to better inform patients and healthcare professionals about the risks of dependence, addiction, withdrawal, and tolerance. These medicines, widely prescribed to treat conditions such as neuropathic pain, anxiety, and insomnia, will now carry the clear warning: “May cause addiction, dependence, and withdrawal reactions.”
Patient information leaflets will also be updated to include precise definitions of dependence and addiction, improved guidance on safely tapering and stopping use, and advice to encourage open conversations with healthcare providers throughout treatment. The move comes after a thorough review by the Commission on Human Medicines (CHM), which highlighted the importance of empowering patients with clear information while ensuring that these medicines continue to provide therapeutic benefits safely.
Dr Alison Cave, MHRA Chief Safety Officer, emphasised the importance of these updates, saying: “Addiction and dependency can happen to anyone taking these medicines, even when used as directed. That’s why we are strengthening warnings so patients and healthcare professionals can better understand the risks. These medicines remain valuable treatments for many patients, and it’s important they have the information they need to use them safely.”
The review also includes guidance for avoiding concomitant use with opioids or alcohol and stresses the dangers of sharing medication with others. The CHM has recommended ongoing engagement with healthcare professionals to support training and develop further resources to ensure safe prescribing and usage.
These changes are particularly relevant for diaspora communities in the UK, where awareness around prescription medicine risks may vary due to cultural differences in healthcare access or communication barriers. Clearer warnings and patient resources aim to empower all patients, including migrant and diaspora populations, to make informed decisions about their treatment and to seek advice when needed.
The MHRA will continue to monitor the safety of these medicines and will take further regulatory action if necessary. Patients are advised not to stop their medication without consulting a healthcare professional, as sudden cessation could lead to withdrawal symptoms. Anyone experiencing suspected side effects should speak to a healthcare provider and report them directly via the MHRA Yellow Card scheme.
The changes will be implemented gradually by manufacturers, and additional resources and guidance can be found in the MHRA’s Drug Safety Update. This initiative follows the MHRA’s earlier work on opioids and forms part of a broader programme addressing dependency-forming medicines across the UK.
By strengthening warnings and improving access to safety information, the MHRA aims to protect all patients, including those in diaspora communities, ensuring that everyone can use prescription medicines safely and with confidence.
